Electron spin resonance in the SS=1/2 quasi-one-dimensional antiferromagnet with Dzyaloshinskii-Moriya interaction BaCu2_2Ge2_2O7_7

We have investigated the electron spin resonance (ESR) on single crystals of BaCu$_2$Ge$_2$O$_7$ at temperatures between 300 and 2 K and in a large frequency band, 9.6 -134 GHz, in order to test the predictions of a recent theory, proposed by Oshikawa and Affleck (OA), which describes the ESR in a $S$=1/2 Heisenberg chain with the Dzyaloshinskii-Moriya interaction. We find, in particular, that the ESR linewidth, $\Delta H$, displays a rich temperature behavior. As the temperature decreases from $T_{max}/2\approx$ 170 K to 50 K, $\Delta H$ shows a rapid and linear decrease, $\Delta H \sim T$. At low temperatures, below 50 K, $\Delta H$ acquires a strong dependence on the magnetic field orientation and for $H \| c$ it shows a $(h/T)^2$ behavior which is due to an induced staggered field $h$, according to OA's prediction

Magnetic anisotropy in epitaxial Mn5Ge3 films

High crystalline quality Mn 5 Ge 3 films with thicknesses ranging 4–200 nm have been grown on Ge(111) substrates by solid phase epitaxy. The basal hexagonal plane of Mn 5 Ge 3 is in epitaxy with the Ge(111) plane. Magnetic properties of the films have been investigated as a function of the film thickness and the magnetization curves have been analyzed using a theory that includes a description of magnetic domains in uniaxial thin films. The results clearly indicate the existence of a critical thickness below which the magnetic stripe phase disappears. We have determined the value of this thickness to lie between 10 and 25 nm from the analysis of experimental magnetization curves and the theoretical fit of the in-plane remanent magnetization. Although analogies can be drawn between the behavior observed in our system and that of hcp Co, we have shown that the critical thickness is considerably smaller in Mn 5 Ge 3 ; this has the potential to open new fields of applications for Mn 5 Ge 3 thin films in magnetic recording and spintronics

Cross-relaxation and phonon bottleneck effects on magnetization dynamics in LiYF4:Ho3+

Frequency and dc magnetic field dependences of dynamic susceptibility in diluted paramagnets LiYF$_4$:Ho$^{3+}$ have been measured at liquid helium temperatures in the ac and dc magnetic fields parallel to the symmetry axis of a tetragonal crystal lattice. Experimental data are analyzed in the framework of microscopic theory of relaxation rates in the manifold of 24 electron-nuclear sublevels of the lowest non-Kramers doublet and the first excited singlet in the Ho$^{3+}$ ground multiplet $^5I_8$ split by the crystal field of S$_4$ symmetry. The one-phonon transition probabilities were computed using electron-phonon coupling constants calculated in the framework of exchange charge model and were checked by optical piezospectroscopic measurements. The specific features observed in field dependences of the in- and out-of-phase susceptibilities (humps and dips, respectively) at the crossings (anti-crossings) of the electron-nuclear sublevels are well reproduced by simulations when the phonon bottleneck effect and the cross-spin relaxation are taken into account

Quantum Monte Carlo study of a resonant Bose-Fermi mixture

We study resonant Bose-Fermi mixtures at zero temperature, with different relative concentrations of the bosons. We use for the first time a Quantum Monte Carlo method with Fixed-Node approxima- tion, to explore the system from the weak to the strong coupling limit. A repulsive interaction among bosons is introduced to provide stability to the bosonic component. Beyond the unitarity limit, the res- onant attractive interaction supports a bound fermionic dimer. At the many-body level, increasing the boson-fermion coupling the system undergoes a quantum phase transition from a state with condensed bosons immersed in a Fermi sea, to a normal Fermi-Fermi mixture of the composite fermions and the bare fermions in excess. We obtain the equation of state and we characterize the momentum distributions both in the weakly and in the strongly interacting limits. We compare Quantum Monte Carlo results to T-matrix calculations, finding interesting signatures of the different many-body ground states

Outcome of children with acute leukemia given HLA-haploidentical HSCT after ab T-cell and B-cell depletion

Allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-haploidentical relative (haplo-HSCT) is a suitable option for children with acute leukemia (AL) either relapsed or at high-risk of treatment failure. We developed a novel method of graft manipulation based on negative depletion of ab T and B cells and conducted a prospective trial evaluating the outcome of children with AL transplanted with this approach. Eighty AL children, transplanted between September 2011 and September 2014, were enrolled in the trial. All children were given a fully myeloablative preparative regimen. Anti–T-lymphocyte globulin from day 25 to 23 was used for preventing graft rejection and graft-versus-host disease (GVHD); no patient received any posttransplantation GVHD prophylaxis. Two children experienced primary graft failure. The cumulative incidence of skin-only, grade 1-2 acute GVHD was 30%; no patient developed extensive chronic GVHD. Four patients died, the cumulative incidence of nonrelapse mortality being 5%, whereas 19 relapsed, resulting in a 24% cumulative incidence of relapse. With a median follow-up of 46 months for surviving patients, the 5-year probability of chronic GVHD-free, relapse-free survival (GRFS) is 71%. Total body irradiation–containing preparative regimen was the only variable favorably influencing relapse incidence and GRFS. The outcomes of these 80 patients are comparable to those of 41 and 51 children given transplantation from an HLA-identical sibling or a 10/10 allelic-matched unrelated donor in the same period. These data indicate that haplo-HSCT after ab T- and B-cell depletion represents a competitive alternative for children with AL in need of urgent allograft. This trial was registered at www.clinicaltrials.gov as #NCT01810120

Evolution of the cosmic ray anisotropy above 10^{14} eV

The amplitude and phase of the cosmic ray anisotropy are well established experimentally between 10^{11} eV and 10^{14} eV. The study of their evolution into the energy region 10^{14}-10^{16} eV can provide a significant tool for the understanding of the steepening ("knee") of the primary spectrum. In this letter we extend the EAS-TOP measurement performed at E_0 around 10^{14} eV, to higher energies by using the full data set (8 years of data taking). Results derived at about 10^{14} and 4x10^{14} eV are compared and discussed. Hints of increasing amplitude and change of phase above 10^{14} eV are reported. The significance of the observation for the understanding of cosmic ray propagation is discussed.Comment: 4 pages, 3 figures, accepted for publication on ApJ Letter

Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial.

BACKGROUND: The early use of broad-spectrum antibiotics remains the cornerstone for the treatment of neonatal late onset sepsis (LOS). However, which antibiotics should be used is still debatable, as relevant studies were conducted more than 20 years ago, recruited in single centres or countries, evaluated antibiotics not in clinical use anymore and had variable inclusion/exclusion criteria and outcome measures. Moreover, antibiotic-resistant bacteria have become a major problem in many countries worldwide. We hypothesized that efficacy of meropenem as a broad-spectrum antibiotic is superior to standard of care regimens (SOC) in empiric treatment of LOS and aimed to compare meropenem to SOC in infants aged 44 weeks meeting the Goldstein criteria of sepsis, were randomized in a 1:1 ratio to receive meropenem or one of the two SOC regimens (ampicillin+gentamicin or cefotaxime+gentamicin) chosen by each site prior to the start of the study for 8-14 days. The primary outcome was treatment success (survival, no modification of allocated therapy, resolution/improvement of clinical and laboratory markers, no need of additional antibiotics and presumed/confirmed eradication of pathogens) at test-of-cure visit (TOC) in full analysis set. Stool samples were tested at baseline and Day 28 for meropenem-resistant Gram-negative organisms (CRGNO). The primary analysis was performed in all randomised patients and in patients with culture confirmed LOS. Proportions of participants with successful outcome were compared by using a logistic regression model adjusted for the stratification factors. From September 3, 2012 to November 30th 2014, total of 136 patients (instead of planned 275) in each arm were randomized; 140 (52%) were culture positive. Successful outcome at TOC was achieved in 44/136 (32%) in the meropenem arm vs. 31/135 (23%) in the SOC arm (p = 0.087). The respective numbers in patients with positive cultures were 17/63 (27%) vs. 10/77 (13%) (p = 0.022). The main reason of failure was modification of allocated therapy. Treatment emergent adverse events occurred in 72% and serious adverse events in 17% of patients, the Day 28 mortality was 6%. Cumulative acquisition of CRGNO by Day 28 occurred in 4% of patients in the meropenem and 12% in the SOC arm (p = 0.052). CONCLUSIONS: Within this study population, we found no evidence that meropenem was superior to SOC in terms of success at TOC, short term hearing disturbances, safety or mortality were similar in both treatment arms but the study was underpowered to detect the planned effect. Meropenem treatment did not select for colonization with CRGNOs. We suggest that meropenem as broad-spectrum antibiotic should be reserved for neonates who are more likely to have Gram-negative LOS, especially in NICUs where microorganisms producing extended spectrum- and AmpC type beta-lactamases are circulating